BU-32: A novel proteasome inhibitor for breast cancer

Breast Cancer Research

Volumn 11, Issue 5, 2009, Pages

  Agyin, Joseph K ^a   Santhamma, Bindu ^a   Nair, Hareesh B ^a   Roy, Sudipa S ^a   Tekmal, Rajeshwar R ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; BU 32; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BID; PROTEIN P21; PROTEIN P27; PROTEIN P53; TIE 1 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; BORONIC ACID DERIVATIVE; CHYMOTRYPSIN; NSC D750499 S; NSC D750499-S; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE TUMOR; BREAST TUMOR; CELL GROWTH; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; BORONIC ACIDS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHYMOTRYPSIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77449117724     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2411     Document Type: Article

References (60)

1. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005, 6:79-87. 10.1038/nrm1552, 15688069.
2. Dalton WS. The proteasome. Semin Oncol 2004, 31:3-9. discussion 33., 10.1053/j.seminoncol.2004.10.012, 15799238.
3. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758. 10.1016/S1074-5521(01)00056-4, 11514224.
4. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006, 14:451-456. 10.1016/j.str.2005.11.019, 16531229.
5. Orlowski M, Cardozo C, Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 1993, 32:1563-1572. 10.1021/bi00057a022, 8431436.
6. Kisselev AF, Goldberg AL. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 2005, 398:364-378. 10.1016/S0076-6879(05)98030-0, 16275343.
7. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995, 268:533-539. 10.1126/science.7725097, 7725097.
8. Brannigan JA, Dodson G, Duggleby HJ, Moody PC, Smith JL, Tomchick DR, Murzin AG. A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature 1995, 378:416-419. 10.1038/378416a0, 7477383.
9. Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 2004, 1695:33-44. 10.1016/j.bbamcr.2004.09.025, 15571807.
10. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006, 5:665-675. 10.1158/1535-7163.MCT-05-0147, 16546981.
11. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5:1062-1075. 10.1038/sj.cdd.4400436, 9894613.
12. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997, 272:12893-12896. 10.1074/jbc.272.20.12893, 9148891.
13. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000, 6:3719-3728.
14. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
15. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
16. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360. 10.1038/nrc1361, 15122206.
17. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, Irvine AE. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006, 66:6379-6386. 10.1158/0008-5472.CAN-06-0605, 16778216.
18. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005, 104:1794-1807. 10.1002/cncr.21414, 16178003.
19. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498. 10.1056/NEJMoa043445, 15958804.
20. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5:2638-2645.
21. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675. 10.1200/JCO.2005.03.108, 15613697.
22. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684. 10.1200/JCO.2005.02.050, 15613699.
23. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639. 10.1200/JCO.2005.11.030, 15659509.
24. Orlowski RZ, Dees EC. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 2003, 5:1-7. 154126, 12559038, 10.1186/bcr460.
25. Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V. Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer 2004, 5:148-157. 10.3816/CBC.2004.n.020, 15245620.
26. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004, 22:115-119. 10.1200/JCO.2004.07.165, 14701773.
27. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617. 10.1056/NEJMoa030288, 12826635.
28. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427. 10.1200/JCO.2002.01.133, 12431963.
29. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121. 10.1200/JCO.2004.02.106, 15169797.
30. Loidl G, Groll M, Musiol HJ, Ditzel L, Huber R, Moroder L. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem Biol 1999, 6:197-204. 10.1016/S1074-5521(99)80036-2, 10099130.
31. Loidl G, Groll M, Musiol HJ, Huber R, Moroder L. Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 1999, 96:5418-5422. 21874, 10318898, 10.1073/pnas.96.10.5418.
32. Loidl G, Musiol HJ, Groll M, Huber R, Moroder L. Synthesis of bivalent inhibitors of eucaryotic proteasomes. J Pept Sci 2000, 6:36-46. 10.1002/(SICI)1099-1387(200001)6:1<36::AID-PSC232>3.0.CO;2-2, 10674718.
33. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111:1654-1664. 2214767, 18006697, 10.1182/blood-2007-08-105601.
34. Arendt CS, Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci USA 1997, 94:7156-7161. 23776, 9207060, 10.1073/pnas.94.14.7156.
35. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 1997, 272:25200-25209. 10.1074/jbc.272.40.25200, 9312134.
36. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006, 281:8582-8590. 10.1074/jbc.M509043200, 16455650.
37. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 2005, 45:465-476. 10.1146/annurev.pharmtox.45.120403.100037, 15822185.
38. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005, 2:357-362. 10.1038/nmeth759, 15846363.
39. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000, 275:21648-21652. 10.1074/jbc.M001083200, 10801801.
40. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003, 101:1530-1534. 10.1182/blood-2002-08-2543, 12393500.
41. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004, 95:176-180. 10.1111/j.1349-7006.2004.tb03200.x, 14965369.
42. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001, 82:110-122. 10.1002/jcb.1150, 11400168.
43. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003, 63:7338-7344.
44. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000, 97:3850-3855. 18105, 10725400, 10.1073/pnas.070047997.
45. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005, 5:18. 1164423, 15929791, 10.1186/1475-2867-5-18.
46. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007, 67:6383-6391. 10.1158/0008-5472.CAN-06-4086, 17616698.
47. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003, 9:1145-1154.
48. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992, 89:7491-7495. 49736, 1323840, 10.1073/pnas.89.16.7491.
49. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994, 91:3602-3606. 43628, 8170954, 10.1073/pnas.91.9.3602.
50. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001, 8:210-218. 10.1038/sj.cdd.4400801, 11319603.
51. Cusack JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001, 61:3535-3540.
52. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647. 10.1074/jbc.M200360200, 11872748.
53. McConkey DJ. Bortezomib paradigm shift in myeloma. Blood 2009, 114:931-932. 10.1182/blood-2009-06-223230, 19643992.
54. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052. 10.1182/blood-2009-01-199604, 19436050.
55. Seon BK. Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer 2002, 99:310-311. 10.1002/ijc.10378, 11979450.
56. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006, 66:184-191. 10.1158/0008-5472.CAN-05-1195, 16397231.
57. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001, 86:23-33.
58. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci 1999, 4:D141-D152. 10.2741/Ortéga, 9924144.
59. Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, Gerritsen ME. Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 2002, 22:1797-1803. 10.1161/01.ATV.0000038995.31179.24, 12426207.
60. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001, 276:3222-3230. 10.1074/jbc.M002016200, 11058584.